Skip to content

Contribution of the Kinematic Theory in the Early Differential Diagnosis of the Parkinson's Disease

Contribution of the Kinematic Theory in the Early Differential Diagnosis of the Parkinson's Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06161636
Enrollment
90
Registered
2023-12-08
Start date
2020-02-19
Completion date
2028-12-31
Last updated
2025-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Parkinson Disease, Parkinsonian Syndromes

Brief summary

The working hypotheses are as follows: #1 The processing of performance signals by automated lognormal segmentation and the extraction of the parameters of interest will make it possible to distinguish groups of patients from healthy elderly subjects. #2 The three instrumental approaches will not have the same degree of reliability as a predictive biomarker of clinical diagnosis established by consensus.

Detailed description

The strength of this study is to compares three refined parametric approaches drawn from functions mediated by very different neuromuscular programs (visually guided voluntary movement control to perform trajectories with the hand or arm versus vocal control) among two groups of patients and a healthy group. Its weakness lies in the lack of multimodal methods to accurately confirm clinical diagnosis and the predictive reliability of patient performance. These modalities are too costly to be included in this project. However, different oculovisual measurement standards such as optical coherence tomography, hyperspectral imaging (OPTINA Diagnostics Inc.), and eye tracking will be used at the School of Optometry, University of Montreal. There is indeed a remodeling of the retina and oculomotor changes in Parkinson's Disease (PD) and these non-invasive techniques, which have been accepted for several years, will be used in patients in support of their clinical diagnosis compared to normal subjects.

Interventions

None listed

Sponsors

Optina Diagnostics Inc.
CollaboratorINDUSTRY
Centre hospitalier de l'Université de Montréal (CHUM)
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Being diagnosed with Parkinsonism including idiopathic Parkinson's disease or a related syndrome; * Have motor symptoms of Parkinsonism for 6 years or less; * Be a healthy volunteer subject in good general health with no prior neurological history; * Age between 50-75 years old; * If applicable, be able to safely leave home in the morning without having taken antiparkinsonian medication for the past 12 hours.

Exclusion criteria

* Major neurocognitive disorders; * History of other neurological conditions, such as ischemic or hemorrhagic stroke, paralysis of a limb, traumatic brain injury, epilepsy, orofacial dystonia, essential tremor; * History of oromandibular or laryngeal procedures; * Uncorrected deafness; * Any contraindication to pupillary dilation.

Design outcomes

Primary

MeasureTime frameDescription
Lognormal primitivesDay 1Velocity profiles generated for simple movements (strokes) and certain vocal frequencies (formants), transformed to fit into the lognormal model

Secondary

MeasureTime frameDescription
Optical Coherence Tomography measuresDay 1Measures of thickness for macula, fovea, peripapillary retinal nerve fiber layer, divided in quadrants, expressed in microns.
Movement Disorder Society-Unified Parkinson's Disease Rating Scale section IIIDay 1Motor rating in the practically defined unmedicated state, in points
Radboud Oral Motor Inventory for Parkinson's DiseaseDay 1Clinical tool to evaluate perceived problems with speech, swallowing, and saliva in subjects with parkinsonism, in points

Countries

Canada

Contacts

Primary ContactPierre Blanchet, MD
pierre.j.blanchet@umontreal.ca514-890-8123

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026